JP2005500981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500981A5 JP2005500981A5 JP2002557409A JP2002557409A JP2005500981A5 JP 2005500981 A5 JP2005500981 A5 JP 2005500981A5 JP 2002557409 A JP2002557409 A JP 2002557409A JP 2002557409 A JP2002557409 A JP 2002557409A JP 2005500981 A5 JP2005500981 A5 JP 2005500981A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- kit
- pharmaceutically acceptable
- amount
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25665700P | 2000-12-19 | 2000-12-19 | |
| PCT/US2001/048802 WO2002056902A2 (en) | 2000-12-19 | 2001-12-17 | Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005500981A JP2005500981A (ja) | 2005-01-13 |
| JP2005500981A5 true JP2005500981A5 (https=) | 2005-04-21 |
Family
ID=22973061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002557409A Pending JP2005500981A (ja) | 2000-12-19 | 2001-12-17 | ウイルス感染を処置するためのｃｃｒ５アンタゴニストおよびｄｐ−１７８ポリペプチド |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050065319A1 (https=) |
| EP (1) | EP1385534A2 (https=) |
| JP (1) | JP2005500981A (https=) |
| CN (1) | CN1481251A (https=) |
| AR (1) | AR031931A1 (https=) |
| BR (1) | BR0116253A (https=) |
| CA (1) | CA2431919A1 (https=) |
| HU (1) | HUP0302241A3 (https=) |
| MX (1) | MXPA03005526A (https=) |
| NO (1) | NO20032769L (https=) |
| WO (1) | WO2002056902A2 (https=) |
| ZA (1) | ZA200304560B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2400553A (en) * | 2003-04-14 | 2004-10-20 | Cipla Ltd | Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof |
| AU2004251228B2 (en) * | 2003-05-16 | 2008-04-24 | University Of Maryland Biotechnology Institute | Compositions for down-regulation of CCR5 expression and methods of use therefor |
| JP2008520684A (ja) | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Ｉｌ−１３に対する完全ヒトモノクローナル抗体 |
| US20070123538A1 (en) * | 2005-11-30 | 2007-05-31 | Schering Corporation | Compositions comprising a combination of CCR5 and CXCR4 antagonists |
| US20100152301A1 (en) * | 2005-12-01 | 2010-06-17 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Treatment of Viral Infections |
| EP1886696A1 (en) * | 2006-08-03 | 2008-02-13 | Endotis Pharma | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins |
| WO2013127299A1 (zh) * | 2012-02-28 | 2013-09-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 用于抑制hiv的多肽及其作用靶点 |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| AU723537B2 (en) * | 1995-06-07 | 2000-08-31 | Trimeris Inc. | The treatment of HIV and other viral infections using combinatorial therapy |
| US6281331B1 (en) * | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| US6387930B1 (en) * | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| CN1349408A (zh) * | 1999-05-04 | 2002-05-15 | 先灵公司 | 聚乙二醇化干扰素α－CCR5拮抗剂联合HIV疗法 |
| HK1039330B (en) * | 1999-05-04 | 2005-12-09 | Schering Corporation | Piperidine derivatives useful as ccr5 antagonists |
| US6689765B2 (en) * | 1999-05-04 | 2004-02-10 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
-
2001
- 2001-06-11 US US10/168,295 patent/US20050065319A1/en not_active Abandoned
- 2001-12-17 MX MXPA03005526A patent/MXPA03005526A/es unknown
- 2001-12-17 WO PCT/US2001/048802 patent/WO2002056902A2/en not_active Ceased
- 2001-12-17 CA CA002431919A patent/CA2431919A1/en not_active Abandoned
- 2001-12-17 EP EP01993303A patent/EP1385534A2/en not_active Withdrawn
- 2001-12-17 CN CNA01820919XA patent/CN1481251A/zh active Pending
- 2001-12-17 JP JP2002557409A patent/JP2005500981A/ja active Pending
- 2001-12-17 BR BRPI0116253-5A patent/BR0116253A/pt not_active IP Right Cessation
- 2001-12-17 HU HU0302241A patent/HUP0302241A3/hu unknown
- 2001-12-17 AR ARP010105840A patent/AR031931A1/es unknown
-
2003
- 2003-06-11 ZA ZA2003/04560A patent/ZA200304560B/en unknown
- 2003-06-18 NO NO20032769A patent/NO20032769L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2238277T3 (es) | Terapia anti-vih con una combinacion de un interferon alfa-pegilado y un antagonista de ccr5. | |
| JP2021063088A5 (https=) | ||
| ES2844629T3 (es) | Tratamiento de la infección por el virus de la hepatitis delta | |
| ES2728405T3 (es) | Tratamiento de la infección por virus de hepatitis delta | |
| CA2440111A1 (en) | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative | |
| CA2908313A1 (en) | Hepatitis c viral infection treatment using a combination of compounds | |
| JP2005527547A5 (https=) | ||
| JP2005500981A5 (https=) | ||
| JP2006511538A (ja) | 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用 | |
| US20040076609A1 (en) | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy | |
| JP2003525907A (ja) | Ｈｉｖ免疫アジュバント治療 | |
| RU2004121687A (ru) | Композиции, содержащие эпотилоны, и их применение для лечения карциноидного синдрома | |
| RU2203047C2 (ru) | Композиция для снижения содержания церамидов | |
| WO2002056902A2 (en) | Ccr5 antagonist and dp-178 polypeptide for treating viral infections | |
| EP0218453B1 (en) | Improved antiinflammatory compositions and methods | |
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| RU2002126216A (ru) | Фармацевтическая композиция для лечения и профилактики фиброза и цирроза печени | |
| WO2007013677A1 (ja) | インターフェロン作用物質の活性増強剤 | |
| JP2005531589A5 (https=) | ||
| RU2188659C1 (ru) | Фармацевтическая композиция для терапии человека, обладающая иммунотропным действием | |
| WO2008041882A1 (fr) | Procédé pour agir sur les virus au moyen d'une substance à base de 2,8-dithioxo-1h- pyrano[2,3-d;6,5-d'] dipyrimidine et de leurs analogues 10-aza (et variantes) | |
| AU2002245148A1 (en) | CCR5 antagonist and DP-178 polypeptide for treating viral infections | |
| JP2004529893A5 (https=) | ||
| RU2294367C2 (ru) | СПОСОБ ВОЗДЕЙСТВИЯ НА ВИРУСЫ ПУТЕМ ИСПОЛЬЗОВАНИЯ ВЕЩЕСТВА НА ОСНОВЕ 2,8-ДИТИОКСО-1H-ПИРАНО[2,3-d; 6,5-d`] ДИПИРИМИДИНА И ИХ 10-АЗА-АНАЛОГОВ (ВАРИАНТЫ) | |
| RU2005113710A (ru) | Применение антител к рецептору ил-2 для предотвращения токсичности, ассоциированной с амфотерицином при лечении грибковых заболеваний |